Literature DB >> 30108026

Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.

Simon Soudet1, David Fajgenbaum2, Claire Delattre3, Alexandra Forestier4, Eric Hachulla5, Pierre Yves Hatron5, David Launay6, Louis Terriou4.   

Abstract

Patients with HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) experience systemic inflammatory symptoms and polyclonal lymphoproliferation due to an unknown etiology. Schnitzler's syndrome (SS) is characterized by recurrent urticarial rash, monoclonal IgM gammopathy, and other clinical signs of inflammation. To our knowledge, we report the first case of iMCD associated with SS and the fourth case of anakinra inducing a complete response for an iMCD patient. A forty-four year old woman with a history of a recurrent urticarial rash, presented to our hospital complaining of 6 months of night sweats, fever, chronic urticaria, iliac bone pain, and generalized lymphadenopathy. An IgM Kappa monoclonal component was measured at 7.8g/L. A lymph node biopsy revealed histopathological features consistent with the plasma cell variant of iMCD. She was diagnosed with SS and iMCD. Anti-IL-1 treatment with anakinra (100mg/day) was introduced. Within 48h, we observed improvement in the fever and the urticarial rash. By one month, we considered the patient in complete remission. Two years later, the remission is persistent while the patient is still under therapy. Though this is only the fourth reported case of anakinra in iMCD, this is yet another case demonstrating the effectiveness of anti-IL-1 blockade in SS. We hypothesize that uncontrolled cytokine production is responsible for both the SS and the iMCD. The etiologies of SS and iMCD are unknown, and future research is necessary.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti IL1 therapy; Multicentric Castleman disease; Physiopathology; Schnitzler syndrome

Mesh:

Substances:

Year:  2018        PMID: 30108026     DOI: 10.1016/j.retram.2018.06.001

Source DB:  PubMed          Journal:  Curr Res Transl Med        ISSN: 2452-3186            Impact factor:   4.513


  3 in total

1.  A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

Authors:  Li Yu; Menghan Shi; Qingqing Cai; Paolo Strati; Fredrick Hagemeister; Qiongli Zhai; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbin Qian; Noriko Iwaki; Yasuharu Sato; Lu Zhang; Jian Li; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-09-18

2.  Clinical Analysis of Castleman's Disease of the Lacrimal Gland.

Authors:  Dongping Li; Dongrun Tang; Fengyuan Sun
Journal:  J Ophthalmol       Date:  2020-11-23       Impact factor: 1.909

3.  Case Report: Extensive Phosphorylation of Interleukin-1 Receptor-Associated Kinase 4 in a Patient With Schnitzler Syndrome.

Authors:  Isabel Hodl; Philipp Bosch; Barbara Dreo; Martin H Stradner
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.